Redundant, secretive, and isolated: When are clinical trials scientifically valid?

Kennedy Institute of Ethics Journal

Volumn 24, Issue 4, 2014, Pages 385-411

  Borgerson, Kirstin ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL (TOPIC); ETHICIST; ETHICS; HUMAN; INFORMATION DISSEMINATION; KNOWLEDGE; META ANALYSIS (TOPIC); METHODOLOGY; PROFESSIONAL STANDARD; REPRODUCIBILITY; SAMPLE SIZE; STANDARDS;

CLINICAL TRIALS AS TOPIC; ETHICISTS; ETHICS COMMITTEES, RESEARCH; HUMANS; INFORMATION DISSEMINATION; KNOWLEDGE; META-ANALYSIS AS TOPIC; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SAMPLE SIZE;

EID: 84920113696     PISSN: 10546863     EISSN: 10863249     Source Type: Journal    
DOI: 10.1353/ken.2014.0029     Document Type: Article

References (57)

1. Anderson, James A. 2006. “The Ethics and Science of Placebo-Controlled Trials: Assay Sensitivity and the Duhem-quine Thesis.” Journal of Medicine and Philosophy(31): 65–81.
2. Anderson, James A., and Jonathan Kimmelman. 2010. “Extending Clinical Equipoise to Phase 1 Trials Involving Patients: Unresolved Problems.” Kennedy Institute of Ethics Journal20 (1): 75–98.
3. Angell, marcia. 2004. The Truth about the Drug Companies: How They Deceive Us and What To Do about It. Toronto: Random House.
4. Biddle, Justin. 2007. “Lessons from the Vioxx Debacle: What the Privatization of Science Can Teach Us about Social Epistemology.” Social Epistemology21 (1): 21–39.
5. Borgerson, Kirstin. 2011. “Amending and Defending Critical Contextual Empiricism.” European Journal for Philosophy of Science1 (3): 435–49.
6. Borgerson, Kirstin. 2013. “Are Explanatory Trials Ethical? Shifting the burden of Justification in Clinical Trial Design.” Theoretical Medicine and Bioethics34 (4): 293–308.
7. Califf, Robert M., Deborah A. Zarin, Judith M. Kramer, Rachel E. Sherman, Laura H. Aberle, and Asba Tasneem. 2012. “Characteristics of Clinical Trials Registered in ClinicalTrials.gov, 2007–2010.” Journal of the American Medical Association307 (17): 1838–47.
8. Chalmers, Iain. 2005. “The Scandalous Failure of Science to Cumulative Evidence Scientifically.” Clinical Trials(2): 229–31.
9. Chalmers, Iain. 2007a. “The lethal Consequences of Failing To make Full Use of All Relevant Evidence About Effects of medical Treatments: The Importance of Systematic Reviews.” In Treating Individuals: From Randomized Trials to Personalized Medicine, edited by Peter Rothwell, 37–58. London: Lancet.
10. Chalmers, Iain. 2007b. “Regulation of Therapeutic Research Is Compromising the Interests of Patients.” International Journal of Pharmaceutical Medicine(21): 395–404.
11. Chalmers, Iain, and Paul Glasziou. 2009. “Avoidable Waste in the Production and Reporting of Research Evidence.” The Lancet374: 86–89.
12. Chalmers, Iain, Paul Glasziou, and Fiona Godlee. 2013. “All Trials must be Registered and the Results Published.” BMJ346: f105.
13. Council for International Organizations of medical Sciences (CIOmS). 2002. International Ethical Guidelines for Biomedical Research Involving Human Subjects. http://www.cioms.ch/index.php/texts-of-guidelines. Accessed may 10, 2013.
14. Dawson, Angus J., and Steve M. Yentis. 2007. “Contesting the Science/Ethics Distinction in the Review of Clinical Research.” Journal of Medical Ethics(33): 165–67.
15. Dickersin, Kay, and Drummond Rennie. 2012. “The Evolution of Trial Registries and Their Use To Assess the Clinical Trial Enterprise.” Journal of the American Medical Association307 (17): 1861–64.
16. Doshi, Peter, and Tom Jefferson. 2012. “Drug Data Shouldn’t be Secret.” New York Times, April 10. http://www.nytimes.com/2012/04/11/opinion/drug-data-shouldnt-be-secret.html?_r=1&.
17. Doshi, Peter, Tom Jefferson, and Chris Del Mar. 2012. “The Imperative to Share Clinical Study Reports: Recommendations from the Tamifu Experience.” PLoS Med 9 (4): e1001201. doi:10.1371/journal.pmed.1001201
18. Eckenwiler, Lisa, Dafna Feinholz, Carolyn Ells, and Toby Schonfeld. 2008. “The Declaration of Helsinki Through a Feminist lens.” The International Journal of Feminist Approaches to Bioethics1 (1): 161–77.
19. Emanuel, Ezekiel J., David Wendler, and Christine Grady. 2000. “What makes Clinical Research Ethical?” Journal of the American Medical Association283: 2701–11.
20. Evans, Emily L. 2010. “In Defense of Valid Design as a Policy Rule.” The American Journal of Bioethics10 (6): 18–19.
21. Freedman, Benjamin. 1987. “Scientific Value and Validity as Ethical Requirements for Research: A Proposed Explication.” IRB: Ethics and Human Research(9): 7–10.
22. Goldacre, Ben. 2013. Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients. Toronto: Signal, McClelland & Stewart.
23. Goldman, Alvin. 1999. Knowledge in a Social World. Oxford: Oxford University Press.
24. Goldman, Alvin. 2002. Pathways to Knowledge: Public and Private. New york: Oxford University Press.
25. Halpern, Scott D., Jason H. T. Karlawish, and Jesse A. Berlin. 2002. “The Continuing Unethical Conduct of Underpowered Clinical Trials.” Journal of the American Medical Association288: 358–62.
26. Howick, Jeremy. 2009. “Questioning the methodological Superiority of ‘Placebo’ over ‘Active’ Controlled Trials.” American Journal of Bioethics9: 34–48.
27. Humaidan, Peter, and Nikolaos P. Polyzos. 2012. “(Meta)analyze This: Systematic Reviews might lose Credibility.” Nature Medicine18 (9): 1321.
28. Humphreys, Keith, Natalya C. Miasel, Janet C. Blodgett, Ingrid L. Fuh, and John W. Finney. 2013. “Extent and Reporting of Patient Non-Enrollment in Influential Randomized Clinical Trials, 2002 to 2010.” Journal of the American Medical Association: Internal Medicine. doi:10.1001/jamain-ternmed.2013.496.
29. Hughes, J. R. 2002. “Letter to The Editor: The Ethics of Underpowered Clinical Trials.” Journal of the American Medical Association288: 2118.
30. International Committee of medical Journal Editors (ICmJE). 2013. “Recommendations for The Conduct, Reporting, Editing and Publication of Scholarly Work in medical Journals.” http://www.icmje.org/recommendations/. Accessed April 22, 2013.
31. Janosky, J. E. 2002. “Letter to the Editor: The Ethics of Underpowered Clinical Trials.” Journal of the American Medical Association288: 2118.
32. Kimmelman, Jonathan, and James A. Anderson. 2012. “Should Preclinical Studies be Registered?” Nature Biotechnology30 (6): 488–89.
33. Kincaid, Harold, John Dupré, and Alison Wylie. 2007. Value-Free Science? Ideals and Illusions. Oxford: Oxford University Press.
34. Lexchin, Joel, Lisa A. Bero, Benjamin Djulbegovic, and Otavio Clark. 2003. “Pharmaceutical Industry Sponsorship and Research Outcome and quality: Systematic Review.” BMJ326: 1167.
35. Longino, Helen. 1990. Science as Social Knowledge. Princeton: Princeton University Press.
36. Longino, Helen. 2002. The Fate of Knowledge. Princeton: Princeton University Press.
37. NCPHS (National Commission for the Protection of Human Subjects of biomedi-cal and behavioral Research). 1979. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, DC: Department of Health, Education, and Welfare. http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html.
38. Nuremberg Code: Directives for Human Experimentation. 1949. Reprinted from Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law No. 10, Vol. 2, pp. 181–182. Washington, DC: U.S. Government Printing Office. http://history.nih.gov/research/downloads/nuremberg.pdf.
39. Montori, Victor M., and Gordon H Guyatt. 2008. “Progress in Evidence-based medicine.” Journal of the American Medical Association300: 1814–16.
40. Reiss, Julian. 2010. “In Favour of a millian Proposal to Reform biomedical Research.” Synthese177: 427–47.
41. Robinson, Karen A., and Steven N. Goodman. 2011. “A Systematic Examination of the Citation of Prior Research in Reports of Randomized, Controlled Trials.” Annals of Internal Medicine154: 50–55.
42. Rogawski, M. A., and H. J. Federoff, “Disclosure of Clinical Trial Results When Product Development Is Abandoned.” Science Translational Medicine3, 102–29 (2011). doi: 10.1126/scitranslmed.3002939
43. Rosoff, Philip M. 2004. “Can Underpowered Clinical Trials be Justified?” IRB: A Review of Human Subjects Research26: 16–19.
44. Sachs, Benjamin. 2010. “Response to Open Peer Commentaries on ‘The Case for Evidence-based Rulemaking’.” The American Journal of Bioethics10 (6): W1–W3.
45. Savulescu, Julian. 2002. “Two Deaths and Two lessons: Is It Time to Review the Structure and Function of Research Ethics Committees?” Journal of Medical Ethics28: 1–2.
46. Savulescu, Julian, Iain Chalmers, and Jennifer Blunt. 1996. “Are Research Ethics Committees behaving Unethically? Some Suggestions for Improving Performance and Accountability.” BMJ313: 1390–93.
47. Savulescu, Julian, and Merle Spriggs. 2002. “The Hexamenthonium Asthma Study and The Death of a Normal Volunteer in Research.” Journal of Medical Ethics28: 3–4.
48. Schrag, Zachary M. 2011. “The Case against Ethics Review in the Social Sciences.” Research Ethics7: 120–31.
49. Shera, Jesse. 1970. Sociological Foundations of Librarianship. New york: Asia Publishing House.
50. Simes, Robert J. 1986. “Publication bias: The Case for an International Registry of Clinical Trials.” Journal of Clinical Oncology4 (10): 1529–41.
51. Sismondo, Sergio, and Mathieu Doucet. 2010. “Publication Ethics and the Ghost management of medical Publications.” Bioethics24 (6): 273–83.
52. Song, F., S. Parekh, and L. Hooper, et al. 2010. “Dissemination and Publication of Research Findings: An Updated Review of Related biases.” Health Technology Access14 (8). doi:10.3310/hta14080.
53. Straus, Sharon E., W. Scott Richardson, Paul Glasziou, and R. Brian Haynes. 2005. Evidence-Based Medicine: How to Practice and Teach EBM, 3d ed. Edinburgh: Churchill livingstone.
54. TCPS-2 (Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, and Social Science and Humanities Research Council of Canada). 2010. Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans. http://www.pre.ethics.gc.ca/eng/policy-politique/initiatives/tcps2-eptc2/Default/. Accessed October 24, 2011.
55. University of Pittsburgh Schools of the Health Sciences. 2009. “Are Researchers Cherry Picking Participants for Studies of Antidepressants?” ScienceDaily, April 29. www.sciencedaily.com/releases/2009/04/090428103108.htm.
56. Wisniewski, Stephen, A. Rush, Andrew Nierenberg, et al. 2009. “Can Phase III Trial Results of Antidepressant medications be Generalized to Clinical Practice? A STAR*D Report.” American Journal of Psychiatry166: 599–607.
57. World Medical Organization. 2008. “WmA Declaration of Helsinki: Ethical Principles for medical Research Involving Human Subjects.” http://www.wma.net/en/30publications/10policies/b3/index.html. Accessed may 10, 2013.